Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
This surprising healthcare stock has been outperforming the markets this year.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.